NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Locus Biosciences

Locus Biosciences

Private
Morrisville, North CarolinaHealthcare & Life Scienceshttps://www.locus-bio.com/

Last Round

Grant

Jan 7, 2026

Total Funding Raised

$142.88M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Locus Biosciences is a biotechnology company that develops engineered bacteriophage-based products aimed at precisely eliminating pathogenic bacteria from the human body through the innovative use of CRISPR-Cas3 technology and safe delivery systems.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

CRISPR-engineered bacteriophagecrPhageprecision antibacterialphage therapyantimicrobial resistanceAMRCRISPR-Cas3AI drug discoverybacteriophage platformsynthetic biologysynbiomicrobiome therapeuticsophthalmic infectionsdrug developmentbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Locus Biosciences Comparables

Compare Locus Biosciences with similar companies based on industry and business-model similarity.

Locus Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SNIPR Biome
87%
Eligo Bioscience
87%
BiomX Inc.
85%

Locus Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 7, 2026
GrantJan 23, 2024
Series BMay 18, 2022
DebtOct 19, 2021
GrantNov 10, 2020
Corporate Funding
Sep 30, 2020

Key People

Founding team and executive leadership

Paul G.

Chief Executive Officer

Executive Team

Nick Conley

Vice President Of Technology, R D, Chief Technology Officer

Executive Team

Locus Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 7, 2026

    $24M grant awarded by BARDA and PHME.

  • Oct 28, 2025

    Developing therapies for ophthalmic bacterial infections with Viatris.

Locus Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Locus Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Locus Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersMorrisville, North Carolina
Employee Range60
Year Founded2015
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.